Modality
Multispecific
MOA
Cl18.2
Target
JAK2
Pathway
mTOR
SCDEwing Sarcoma
Development Pipeline
Preclinical
~Aug 2012
→ ~Nov 2013
Phase 1
~Feb 2014
→ ~May 2015
Phase 2
~Aug 2015
→ ~Nov 2016
Phase 3
~Feb 2017
→ ~May 2018
NDA/BLA
Aug 2018
→ Apr 2029
NDA/BLACurrent
NCT04526575
1,411 pts·SCD
2018-08→2029-04·Recruiting
NCT06427650
2,996 pts·SCD
2025-02→2026-03·Active
4,407 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-231w agoPh3 Readout· SCD
2029-04-233.1y awayPh3 Readout· SCD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Recruit…
NDA/BLA
Active
Catalysts
Ph3 Readout
2026-03-23 · 1w ago
SCD
Ph3 Readout
2029-04-23 · 3.1y away
SCD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04526575 | NDA/BLA | SCD | Recruiting | 1411 | PASI75 |
| NCT06427650 | NDA/BLA | SCD | Active | 2996 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Teravorutinib | Illumina | Phase 2 | JAK2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 | |
| Tiratapinarof | Intellia | NDA/BLA | APOC3 | |
| AXS-4984 | Axsome | Preclinical | JAK2 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 | |
| Zenorelsin | Disc Medicine | NDA/BLA | JAK2 |